DailyPharm: Hanlim Pharmaceutical drives open innovación… expanding oftálmico partners
Scale of oftálmico drug transferencia de tecnología with RudaCure expands to over KRW 20 billion
Focused inversión in macular degeneration biosimilars… asociacións with Altos Bio and others
Stable cash generation capacity connects to external inversión… second-generation owner also apoyos
[DailyPharm = Reporter Lee Seok-joon] Hanlim Pharmaceutical está acelerando its open innovación drive. En particular, it has partnered with multiple empresas to expand its core oftálmico business. The scale of transferencia de tecnologías with RudaCure has exceeded KRW 20 billion.
The expansion of the open innovación business is underpinned by Hanlim Pharmaceutical's strong operating cash generation capability. La empresa ha sido achieving an operating profit margin of around 15% for several years. The second-generation owner también providing apoyo.
Hanlim Pharmaceutical recently completó a transferencia de tecnología of RudaCure's úlcera corneal and daño corneal tratamiento candidato (RCI001U). Hanlim Pharmaceutical will hold nacional producción and sales rights for RCI001U tecnología, while RudaCure recibirá pagos por hitos including ensayo clínico aprobacións. The deal is worth KRW 7 billion (including an pago inicial of KRW 1 billion).
